Non-Darwinian Dynamics in Therapy-Induced Cancer Drug Resistance

Related Content

• 

  How Glioblastoma Resists Treatment – and Ways to Prevent It

   Posted on July 9, 2024

  Glioblastoma is one of the deadliest and most aggressive forms of primary brain cancer in adults and is known for its ability to resist treatment and to recur. ISB researchers have made breakthrough discoveries in understanding the mechanisms behind acquired resistance, focusing on a rare and stubborn group of cells within tumors called glioma stem-like cells.

• Breakthrough T Cell Discovery Has Huge Potential for Engineering Custom Immune Responses

   Posted on February 2, 2024

  In a breakthrough discovery that changes how we understand T cells and with implications of how we can better engineer custom immune responses to fight disease, Institute for Systems Biology researchers showed that the different disease-fighting functions of different T cells are determined by the genetically encoded T-cell receptor sequence that are unique to those cells.

• How Immune Cells ‘See’ and Respond to Mutations in Cancer Cells

   Posted on March 8, 2023

  In a just-published paper in the journal Nature, a collaborative team of researchers from ISB, UCLA, PACT Pharma, and beyond analyzed T-cell responses in melanoma patients who were treated with different immune checkpoint inhibitors, and how those responses evolved over time.

• In First-of-Its-Kind Trial, Scientists Use CRISPR to Treat Cancer

   Posted on November 11, 2022

  Scientists for the first time have used CRISPR to substitute a gene to treat patients with cancer. The remarkable findings were published in the journal Nature and presented at the Society for Immunotherapy of Cancer (SITC) 2022.

• Improving Cancer Care for All: A Conversation with Drs. Jim Heath, Jim Allison and Lynda Chin

   Posted on September 30, 2022

  ISB President Dr. Jim Heath talks with Nobel laureate and Executive Director of the Immunotherapy Platform at MD Anderson Cancer Center Dr. Jim Allison and Apricity Health CEO Dr. Lynda Chin. Drs. Heath, Allison and Chin discuss disparities in cancer care and ways to bring state-of-the-art care from big cities and major academic centers to rural and underserved areas.

• 

  ISB Leading NCI Comprehensive Cancer Center to Study Sequential Targeted Inhibitors and Immunotherapies

   Posted on September 22, 2022

  The NCI awarded ISB a 5-year, $13 million grant to lead a comprehensive cancer center and study sequential combinations of targeted inhibitors and immunotherapies. The program is designed to determine if the treatments yield greater patient benefit when administered in sequence rather than as monotherapies or as simultaneously administered combinations.

• 

  Dr. Jim Heath Named Fellow of AACR Academy Class of 2022

   Posted on March 22, 2022

  Dr. Jim Heath was announced as a newly elected Fellow of the American Academy for Cancer Research (AACR) Academy Class of 2022. “I am honored and humbled to be recognized as part of this renowned group of researchers who have done so much to move our understanding of cancer forward,” Heath said.

• Dr. Andrew Magis: Identifying Markers for Cancer Years Before Diagnosis

   Posted on September 29, 2021

  By taking detailed measurements of blood and other biological samples, ISB scientists have shown they can identify markers for cancer years before diagnosis. This was the topic of a recent Research Roundtable presentation delivered by Dr. Andrew Magis, Director of Data Science in ISB’s Health Data Science Lab.

• 

  New Technology Reveals Single Cancer Cells Have Different Appetites for Fatty Acids

   Posted on July 16, 2021

  A recently developed method by the Wei Lab at Institute for Systems Biology (ISB) and University of California, Riverside provides new insights into cancer biology by allowing researchers to show how fatty acids are absorbed by single cells. This work was published in the Journal of the American Chemical Society.

• 

  Looking at Tumors Through a New Lens

   Posted on June 29, 2021

  To improve the efficacy of neoadjuvant immune checkpoint blockade against glioblastoma, researchers are looking for vulnerabilities in surgically removed tissues – a difficulty due to the vast differences within the tumor and between patients. To address this, ISB researchers and their collaborators developed a new way to study tumors.

• 

  Andy Hill CARE Fund Awards $100,000 to ISB's Dr. Wei Wei

   Posted on April 2, 2021

  To advance research at the intersection of COVID-19 and cancer, The Andy Hill CARE Fund has awarded ISB Assistant Professor Dr. Wei Wei a $100,000 grant to study chronic lymphocytic leukemia (CLL), one of the most commonly diagnosed leukemias in the Western world that mainly affects older individuals.

• 

  A Better Way to Find Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients

   Posted on March 9, 2021

  Despite the aggressive nature of Non-Small Cell Lung Cancer (NSCLC), circulating tumor cells that lead to metastases often go undetected in the blood. ISB researchers in Dr. Wei Wei’s lab and their collaborators have developed a novel method to better detect these circulating cells.

• 

  Small, Persistent Increase in the Expression of NOD1 May Promote Cancer Risk

   Posted on January 7, 2021

  ISB researchers have found that a small, persistent increase in the expression of NOD1 could be responsible for higher cancer risks. The research team found that a slight 1.5-fold uptick in NOD1 expression can activate the protein and downstream signaling pathways in a manner similar to vast (30- to 200-fold) overexpression. 

• 

  CRI iAtlas Expands to Interactive Analysis of Data on Immunotherapy Treatments

   Posted on December 18, 2020

  CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.